Piper Sandler Reiterates Overweight on InspireMD, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder has reiterated an Overweight rating on InspireMD (NASDAQ:NSPR) and maintained a price target of $4.5.
September 17, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on InspireMD, maintaining a price target of $4.5. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $4.5 price target by Piper Sandler indicates a positive outlook on InspireMD's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100